These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 8878591)

  • 1. In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients.
    Alcaide F; Carratala J; Liñares J; Gudiol F; Martin R
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2117-20. PubMed ID: 8878591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2071-4. PubMed ID: 8878583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis.
    Mouton JW; Endtz HP; den Hollander JG; van den Braak N; Verbrugh HA
    J Antimicrob Chemother; 1997 May; 39 Suppl A():75-80. PubMed ID: 9511068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci.
    Betriu C; Redondo M; Palau ML; Sánchez A; Gómez M; Culebras E; Boloix A; Picazo JJ
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1838-41. PubMed ID: 10858339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nationwide German multicenter study on the prevalence of antibiotic resistance in streptococcal blood isolates from neutropenic patients and comparative in vitro activities of quinupristin-dalfopristin and eight other antimicrobials.
    Reinert RR; von Eiff C; Kresken M; Brauers J; Hafner D; Al-Lahham A; Schorn H; Lütticken R; Peters G;
    J Clin Microbiol; 2001 May; 39(5):1928-31. PubMed ID: 11326015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients.
    Wisplinghoff H; Reinert RR; Cornely O; Seifert H
    J Clin Microbiol; 1999 Jun; 37(6):1876-80. PubMed ID: 10325340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae.
    Reinert RR; Kresken M; Mechery V; Lemperle M; Lütticken R
    Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):662-5. PubMed ID: 9832271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phenotypes of macrolide, lincosamide, and streptogramin resistant Streptococcus viridans isolated from blood].
    Rodríguez-Avial C; García MM; Rodríguez-Avial I; Picazo JJ
    Rev Esp Quimioter; 1999 Dec; 12(4):346-51. PubMed ID: 10855014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group.
    Pfaller MA; Jones RN; Marshall SA; Edmond MB; Wenzel RP
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):259-63. PubMed ID: 9458983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
    Nakashio S; Iwasawa H; Iino S; Shimada J
    Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of the new ketolide HMR 3647 (telithromycin) in comparison with those of eight other antibiotics against viridans group Streptococci isolated from blood of neutropenic patients with cancer.
    Alcaide F; Benítez MA; Carratalà J; Gudiol F; Liñares J; Martín R
    Antimicrob Agents Chemother; 2001 Feb; 45(2):624-6. PubMed ID: 11158768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the in vitro activity of pristinamycin and quinupristin/dalfopristin against Streptococcus pneumoniae.
    Lozniewski A; Lion C; Mory F; Weber M
    Pathol Biol (Paris); 2000 Jun; 48(5):463-6. PubMed ID: 10949841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrolide resistance mechanisms and in vitro susceptibility patterns of viridans group streptococci isolated from blood cultures.
    Ergin A; Ercis S; Hasçelik G
    J Antimicrob Chemother; 2006 Jan; 57(1):139-41. PubMed ID: 16291867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.
    Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1867-70. PubMed ID: 9303375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children.
    Ioannidou S; Tassios PT; Kotsovili-Tseleni A; Foustoukou M; Legakis NJ; Vatopoulos A
    Int J Antimicrob Agents; 2001 Mar; 17(3):195-201. PubMed ID: 11282264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
    Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
    Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies.
    Pankuch GA; Lichtenberger C; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1653-6. PubMed ID: 8807057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin.
    McWhinney PH; Patel S; Whiley RA; Hardie JM; Gillespie SH; Kibbler CC
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2493-5. PubMed ID: 8285642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells.
    Stout JE; Arnold B; Yu VL
    J Antimicrob Chemother; 1998 Feb; 41(2):289-91. PubMed ID: 9533475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.